CGEM Cullinan Therapeutics
- 23.500
- +0.710+3.12%
- 24.500
- +1.000+4.26%
Cullinan Therapeutics News
Express News | Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial.
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed,
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Edward White maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 3
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination With a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung
Express News | Cullinan Therapeutics Files For Resale Of Up To 14.4M Shares By The Selling Stockholders
Express News | Cullinan Therapeutics Inc Files for Resale of up to 14.4 Mln Shares by the Selling Stockholders - SEC Filing
Express News | Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update
HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating
Cullinan Oncology (CGEM) has an average buy rating and a price target range of $28 to $40, according to analysts polled by Capital IQ. Price: 25.23, Change: -1.49, Percent Change: -5.58
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
Express News | Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Express News | Cullinan Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $28 From $29
Cullinan Therapeutics | 10-Q: Quarterly report
Express News | Cullinan Therapeutics Inc: Qtrly Shr Loss $0.86
Express News | Cullinan Therapeutics: Cash & Investments as of March 31, Plus Gross Proceeds of $280 Mln From April Private Placement Extends Cash Runway Into 2028
Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM
Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM
Express News | Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster s
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
Jennifer Michaelson, Chief Scientific Officer, on May 06, 2024, sold 63,606 shares in Cullinan Therapeutics (CGEM) for $1,796,676. Following the Form 4 filing with the SEC, Michaelson has control over
Analysis
Price Target
No Data
